Mouse apolipoprotein A1(Apo-A1) ELISA Kit

Code CSB-E08104m
Size 96T,5×96T,10×96T
See More Details 24T ELISA kits trial application
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Target Name apolipoprotein A-I
Alternative Names Apoa1Apolipoprotein A-I ELISA kit; Apo-AI ELISA kit; ApoA-I ELISA kit; Apolipoprotein A1) [Cleaved into: Proapolipoprotein A-I ELISA kit; ProapoA-I); Truncated apolipoprotein A-I] ELISA kit
Abbreviation APOA1
Uniprot No. Q00623
Species Mus musculus (Mouse)
Sample Types serum, plasma, cell culture supernates, urine, tissue homogenates
Detection Range 31.25 ng/mL-2000 ng/mL
Sensitivity 7.81 ng/mL
Assay Time 1-5h
Sample Volume 50-100ul
Detection Wavelength 450 nm
Research Area Cardiovascular
Assay Principle quantitative
Measurement Sandwich
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
To assess the linearity of the assay, samples were spiked with high concentrations of mouse Apo-A1 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
1:1000Average %95
Range %90-100
1:2000Average %89
Range %84-95
1:4000Average %85
Range %80-90
1:8000Average %97
Range %92-101
The recovery of mouse Apo-A1 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample TypeAverage % RecoveryRange
Serum (n=5) 9893-104
EDTA plasma (n=4)9995-107
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
20002.214 2.256 2.235 2.062
10001.856 1.890 1.873 1.700
5001.461 1.400 1.431 1.258
2500.964 0.999 0.982 0.809
1250.689 0.672 0.681 0.508
62.50.481 0.491 0.486 0.313
31.250.350 0.368 0.359 0.186
00.172 0.174 0.173  
and FAQs
Storage Store at 2-8°C. Please refer to protocol.
Lead Time 3-5 working days

Target Data

Function Participates in the reverse transport of cholesterol from tissues to the liver for excretion by promoting cholesterol efflux from tissues and by acting as a cofactor for the lecithin cholesterol acyltransferase (LCAT). As part of the SPAP complex, activates spermatozoa motility.
Gene References into Functions
  1. Altered intestinal lymphatic HDL-ApoA-I and miR-223 metabolism in IR and modulation by niacin may provide insight into the intestinal-mediated regulation of the reverse cholesterol transport pathway PMID: 29183962
  2. We developed a chimaeric molecule termed Fibapo in which FGF19 is covalently coupled to apolipoprotein A-I. Fibapo retains FGF19 biological activities but has significantly increased half-life and hepatotropism. Here we evaluated the pro-regenerative activity of Fibapo in two clinically relevant models where liver regeneration may be impaired: acetaminophen (APAP) poisoning, and PH in aged mice. PMID: 28981086
  3. this study indicates that ionic interactions in the C-terminal domain of apoA-I favor self-association and that monomeric apoA-I is more active in solubilizing phospholipid bilayers. PMID: 29578333
  4. These results suggested that apoA-I overexpression could reduce steatosis by decreasing lipid levels and by suppressing endoplasmic reticulum stress and lipogenesis in hepatocytes. ApoA-I expression could significantly reduce hepatic ER stress and lipogenesis in hepatocytes. PMID: 28577569
  5. ABCA1-derived nascent high-density lipoprotein-apolipoprotein AI and lipids metabolically segregate. PMID: 29074589
  6. apoA-I/ABCA1-mediated cholesterol efflux without STAT3 activation can reduce proinflammatory cytokine expression in macrophages. PMID: 26989082
  7. a novel protective role for ApoA-I in colitis and CAC PMID: 26279300
  8. Our results assign a novel role for 4F(apoA-I mimetic peptide ) as a modulator of the TICE pathway and suggest that the anti-inflammatory functions of 4F may be a partial consequence of the codependent intestinal transport of both 4F and cholesterol. PMID: 27199144
  9. Preincubation of endothelial cells with apoA-I protected against the TNF-alpha-induced inhibition of HTR-8/SVneo (trophoblast) cell integration into endothelial (UtMVEC) networks. These data suggest that a healthy lipid profile may affect pregnancy outcomes by priming endothelial cells in preparation for trophoblast invasion. PMID: 27806983
  10. Reductions in Dio1 expression reduce the expression of ApoA-I in a 3,5,3'-triiodothyronine-/thyroid hormone response element-independent manner. PMID: 27150392
  11. apoA-1 deficiency generates changes in the bone cell precursor population that increase adipoblast, and decrease osteoblast production resulting in reduced bone mass and impaired bone quality PMID: 27088511
  12. This study suggests that enhancement of macrophage cholesterol metabolism by PPARgammais not contributed by activating ABCA1 expression and ABCA1-mediated cholesterol efflux to apoAI, which is not involved by CD36 expression either. PMID: 27890613
  13. Mass spectrometry analysis of peptides derived from chemically crosslinked HDL-SAA particles detected multiple crosslinks between apoA1 and SAA, indicating close proximity (within 25 A) of these two proteins on the HDL surface, providing a molecular and structural mechanism for the simultaneous binding of heparin to apoA1 and SAA. PMID: 27105909
  14. results demonstrate that double deletion of Apoe and Apoa1 ameliorated the amyloid pathology. PMID: 26510953
  15. study suggests that apolipoprotein a1 can alleviate obesity related metabolic disease by inducing AMPK dependent mitochondrial biogenesis. PMID: 25982508
  16. ApoA-I can attenuate lymphocyte activation and autoimmunity in Lupus independently of cholesterol transport, through oxidized fatty acid peroxisome proliferator-activated receptor gamma ligands, and it can reduce renal inflammation in glomerulonephritis. PMID: 26466956
  17. KLF14 regulates plasma HDL-C levels and cholesterol efflux capacity by modulating hepatic ApoA-I production. PMID: 26368306
  18. Akt, through its downstream targets, mTORC1 and hence autophagy, negatively regulates cholesterol efflux to apoA-I. PMID: 25415591
  19. macrophage apoAI expression protects against atherosclerosis and dermatitis by reducing cholesterol accumulation and regulating CD4(+) T-cell levels, without affecting serum HDL or tissue macrophage levels. PMID: 25593328
  20. HDL from apoA1 transgenic mice expressing the 4WF isoform is resistant to oxidative loss of function. PMID: 25561462
  21. ApoA1 levels were not associated with AngII-induced abdominal aortic aneurysms in mice. PMID: 26044581
  22. decreased ApoAI synthesis might be accounted for the lower plasma HDL level in ApoCIII transgenic mice PMID: 25969427
  23. MMP-8-deficient mice had significantly lower serum triglyceride (TG) levels (P = 0.003) and larger HDL particles compared with wild-type (WT) mice. However, no differences were observed in the apoA-I levels. PMID: 25550459
  24. Neutrophil recruitment and the neutrophil cytokines, CXCL1/CXCL2, were suppressed in apo(a)transgenic mice in the abdominal aortic aneurysm model. PMID: 24650562
  25. Expression of apoA-I or ABCA1 can reduce steatosis by decreasing lipid storage in hepatocytes through lipid transport and may also reduce endoplasmic reticulum stress, further lessening hepatic steatosis PMID: 24219083
  26. Data from studies in knockout mice suggest that low apoA1 (and thus low HDL) decreases coenzyme Q10 pool, which in turn decreases electron transfer from electron transport complexes II/III in myocardium mitochondria. PMID: 24759932
  27. role of the hydrophobic residues 225-230 of apoA-I for the biogenesis of HDL PMID: 24123812
  28. the alteration of the hydrophobic 218-222 residues of apoA-I disrupts apoA-I/ABCA1 interactions and promotes the generation of defective pre-beta particles that fail to mature into alpha-HDL subpopulations PMID: 23990662
  29. study identifies a previously unknown proteolytic activity of PLA2 that is specific to apoA-I and may contribute to the enhanced catabolism of apoA-I in inflammation and atherosclerosis. PMID: 24523407
  30. Myeloperoxidase-mediated oxidation renders ApoA-I dysfunctional and unable to promote reverse cholesterol transport, mediate beneficial changes in the composition of atherosclerotic plaques, and pacify the inflammatory status of plaque macrophages. PMID: 24407029
  31. DYRK1A overexpression decreases plasma lecithin:cholesterol acyltransferase activity and apolipoprotein A-I levels. PMID: 23920041
  32. In the C57BL/6 context, but not FVB/N, apoA-I decreases inflammatory macrophage recruitment and monocytosis, contributors to lesion formation PMID: 24334873
  33. ApoA1 enhances resolution of allergen-induced airway inflammation through promoting recovery of damaged TJs in the bronchial epithelium. PMID: 23889245
  34. This study reveals a potent immunomodulatory role for apoA1 in the tumor microenvironment. PMID: 23720750
  35. ApoA-I Helsinki promotes accumulation of ACAT1 in a mouse macrophage cell line. PMID: 23456478
  36. Data indicate that in contrast to apoA-I-knock-out (KO) mice, apoA-I transgenic mice were moderately resistant to cecal ligation and puncture (CLP)-induced septic death. PMID: 23658016
  37. Apo (a) could attenuate the adhesion, migration, and homing abilities of endothelial progenitor cells(EPCs) and could impair the angiogenesis ability of EPCs. PMID: 23581552
  38. Hepatocyte-specific Dyrk1a gene transfer rescues plasma apolipoprotein A-I levels and aortic Akt/GSK3 pathways in hyperhomocysteinemic mice. PMID: 23429073
  39. Genome-wide screen for modulation of hepatic apolipoprotein A-I (ApoA-I) secretion. PMID: 23322769
  40. Mouse apoA-I, which has a relatively polar C-terminal domain, binds to human high-density lipoprotein to approximately half the level of human apoA-I. PMID: 23425306
  41. the involvement of apoA-I in diet-induced The accumulation of triglycerides in hepatocytes and its potential role in the treatment of nonalcoholic fatty liver disease, is reported. PMID: 22576368
  42. Reduced biliary sterol output with no change in total faecal excretion was found in mice expressing a human apolipoprotein A-I variant. PMID: 22845860
  43. A de novo, loss-of-function mutation in the ApoA1 gene of the BcA68 strain prematurely truncates the ApoA1 protein and is associated with a deviant HDLc plasma level. PMID: 22805347
  44. OVA-challenged apoA-I(-/-) mice exhibited a phenotype of increased airway neutrophils compared with WT mice. PMID: 22427535
  45. fed pregnant mice, with or without a deficiency of Mthfr, choline-deficient diets and examined levels of ApoAI, PPARalpha, IFNgamma, and IL-10. ApoAI mRNA was reduced in Mthfr(+/-) and ApoAI protein was reduced due to Mthfr deficiency or choline deficiency. PMID: 22259189
  46. naturally occuring polymorphisms significantly alter the protein self-association properties, the ability of the proteins to clear lipid micelles from solution, and their binding affinity for mature mouse HDL PMID: 22402133
  47. The FGF19 effect on APOA was attenuated by transfection of primary hepatocytes with siRNA against the FGF19 receptor 4 (FGFR4). PMID: 22267484
  48. Data show that cells expressing Cav1 have 2.6-fold more apoA-I binding sites than Cav1(-/-) cells although these additional binding sites are not associated with detergent-free lipid rafts. PMID: 21858084
  49. the role of the PCPE2 protein in an in vivo model PMID: 21771977
  50. analysis of reverse cholesterol transport key players and rescue from global inflammation by ApoA-I(Milano) PMID: 19120689
  51. apolipoprotein A-I (apo A-I), the principal apolipoprotein of high density lipoprotein (HDL) particles, is localized on skeletal muscle lipid droplets PMID: 21870882
  52. ApoA-I deficiency in mice is associated with redistribution of apoA-II and aggravated AApoAII amyloidosis. PMID: 21622630
  53. residues D89, E91, and E92 of apoA-I are important for plasma cholesterol and triglyceride homeostasis as well as for the maturation of HDL PMID: 21504968
  54. ApoA-I has an anti-obesity effect in the mouse and such effect is associated with increases in energy expenditure and UCP1 expression in the brown fat tissue. PMID: 20193037
  55. these results suggest that the expression of H-ras12V oncogene leads to elevated levels of ROS and apolipoprotein A-I that contribute to steatosis. PMID: 21600874
  56. the apoA-I variants that cause hypertriglyceridemia in mice have the altered conformation and stability that facilitate their binding to triglyceride-rich lipoproteins PMID: 21288012
  57. APOA-1 is a novel marker of the terminal erythroid maturation of hematopoietic stem cells in both mice and humans. PMID: 20376577
  58. Apolipoprotein A-I deficiency increases cerebral amyloid angiopathy and cognitive deficits in APP/PS1DeltaE9 mice. PMID: 20739292
  59. These data demonstrate that apoA-I plays important roles in limiting pulmonary inflammation and oxidative stress, which if not prevented, will decrease pulmonary artery vasodilatation and increase airway hyperresponsiveness. PMID: 20498409
  60. CD36 influences reverse cholesterol transport and hepatic ApoA-I production PMID: 20360851
  61. Cysteinemia, rather than homocysteinemia, is associated with plasma apolipoprotein A-I levels in hyperhomocysteinemia: lipid metabolism in cystathionine beta-synthase deficiency. PMID: 20537649
  62. the reversible binding of apoA-I to HDL PMID: 19786567
  63. Interaction between the N- and C-terminal domains in apoA-I modulates the stability and lipid-binding properties of the N-terminal helix bundle. PMID: 19239199
  64. Modifying apolipoprotein (apo) A-I mimetic peptides to include a proline-punctuated alpha-helical repeat increases their anti-inflammatory properties as well as allows better mimicry of full-length apoA-I function. PMID: 19433476
  65. Apolipoprotein A-I alpha -helices 7 and 8 modulate high density lipoprotein subclass distribution PMID: 11744719
  66. the role of apoA-I in scavenger receptor BI-mediated HDL cholesteryl ester-selective uptake PMID: 12000760
  67. studies establish a novel binding site for apoA-I on the macrophage extracellular matrix that may function together with ABCA1 in promoting cholesterol efflux PMID: 12050168
  68. Heteronuclear NMR studies of human serum apolipoprotein A-I. PMID: 12062424
  69. ApoAI has a role in apolipoprotein-mediated cholesterol efflux in mice PMID: 12181325
  70. Adenoviral vector-mediated SR-BI overexpression in livers of human apoB transgenic mice reduced plasma HDL-cholesterol and apolipoprotein A-I concentrations to nearly undetectable levels 3 days after adenovirus infusion PMID: 12235173
  71. The central helices of ApoA-I can promote ATP-binding cassette transporter A1 (ABCA1)-mediated lipid efflux PMID: 12488454
  72. APOA1 has a role in regulating ABCA1 expression in macrophages PMID: 12511593
  73. Hepatocyte expression of ABCA1 is central to the lipidation of newly synthesized apoA-I but also contributes to the lipidation of exogenous apoA-I. PMID: 12547832
  74. APOA1 has a role in formation of nascent high density lipoprotein particles PMID: 12928428
  75. Low plasma apoE (1-3 x 10(-8) M) suppresses atherosclerosis by as yet undefined mechanisms, not dependent on the presence of apoA-I or HDL or an increased capacity of serum acceptors for Free Cholesterol efflux PMID: 12951361
  76. In murine macrophage cell line RAW264 cells, cAMP induced expression of ABCA1, release of cellular phospholipid and cholesterol by apoA-I, and reversible binding of apoA-I to the cell. PMID: 14729855
  77. ABCA1-dependent cholesterol mobilization to apoA-I increased new cholesterol synthesis, indicating depletion of the regulatory pool of hepatocyte cholesterol during HDL formation PMID: 14993246
  78. apolipoprotein A-I has a role in protecting against endotoxin toxicity PMID: 15188057
  79. conclude that the main mechanism for HDL assembly by endogenous apoA-I in HepG2 cells is an autocrine-like reaction in which apoA-I is secreted and then interacts with cellular ABCA1 to generate HDL PMID: 15520446
  80. Although ABCA7 does not contribute to apolipoprotein-mediated lipid efflux in resting macrophages, its cell surface location in the kidney suggests that it could serve such a role in tissue microenvironments. PMID: 15520449
  81. analysis of regulation of phospholipid and cholesterol lipidation of apoA-I in hepatocytes PMID: 15797865
  82. Overexpression of apoA-l inhibits atherosclerosis in animal models. PMID: 16099465
  83. apoA-I phospholipidation starts early in the ER and is partially dependent on ABCA1, with the bulk of lipidation by phospholipids and cholesterol occurring in the Golgi and at the plasma membrane, respectively PMID: 16204232
  84. in the atherosclerosis-susceptible human apoB/A-II mouse model, expression of the human apoA-I(M) gene does not have protective advantage over that of the apoA-I gene. PMID: 16285990
  85. Elevated levels of human apoAI in LDL receptor-deficient mice lacking mouse apoAI conferred profound protection against diet-induced over extended periods of time. PMID: 16423356
  86. the phospholipid transfer protein knockout mouse-derived phospholipid-deficient apoA-I was less stable in hepatocyte culture PMID: 16554055
  87. Hcy reduced the levels of apoA-I protein but not mRNA and inhibited apoA-1 protein synthesis in mouse primary hepatocytes. ApoA-I protein was reduced in the plasma and liver, but hepatic apoA-I mRNA was unchanged in CBS(-/-)/apoE(-/-) mice. PMID: 16931800
  88. Knockout mice accumulate a 10-fold greater mass of cholesterol in their skin despite a 1.5- to 2-fold lower plasma cholesterol concentration compared with diet-fed mice. PMID: 17071966
  89. protective function of apoA-I diminishing the burden of nitrative oxidants in mice models of atherosclerosis PMID: 17615369
  90. The study establishes that apoA-I(Leu141Arg)Pisa and apoA-I(Leu159Arg)FIN inhibit an early step in the biogenesis of HDL due to inefficient esterification of the cholesterol of the prebeta1-HDL particles by the endogenous LCAT. PMID: 17711302
  91. Suggest that apoA-I- but not HDL-mediated cholesterol efflux may involve retroendocytosis in macrophages. PMID: 17906976
  92. APN deficiency might cause the impaired HDL assembly by decreasing ABCA1 expression and apoA-I synthesis in the liver. PMID: 17936760
  93. Generates HDL largely in hepatocytes only in the presence of ABCA1. PMID: 18033752
  94. When knock-out hepatocytes were infected with an adenovirus expressing CTalpha, apoAI-dependent PC efflux returned partially, whereas cholesterol efflux and ABCA1 levels were not restored to normal levels. PMID: 18042552
  95. an increased expression of PTX3 mRNA was detected in the aorta of transgenic mice overexpressing human apoA-I, compared to apoA-I knock-out mice. PMID: 18218986
  96. Using adenovirus-mediated gene transfer in apolipoprotein A-I (apoA-I)-deficient mice, we have established that apoA-I mutations inhibit discrete steps in a pathway that leads to the biogenesis and remodeling of high-density lipoprotein (HDL) [review] PMID: 18246469
  97. ATP-binding cassette transporter (ABC) A1 is required for the lipidation of apolipoprotein A-I to generate high density lipoprotein (HDL). PMID: 18385134
  98. Double heterozygous mice lacking one allele of Cbs and Apoa1 develop hyperhomocysteinemia and hypoalphalipoproteinemia together with moderate hypertension. PMID: 18508577
  99. Simvastatin decreased cholesterol levels, but levels of ApoA-I in Mthfr-deficient mice remained lower than those in Mthfr(+/+) mice. PMID: 18540024
  100. the apoCIII enhancer contributes to the maintenance of an active chromatin subdomain of the apoAI/CIII/AIV genes, but not apoAV PMID: 18678879

Show More

Hide All

Subcellular Location Secreted
Protein Families Apolipoprotein A1/A4/E family
Tissue Specificity Major protein of plasma HDL, also found in chylomicrons.
Database Links

KEGG: mmu:11806

STRING: 10090.ENSMUSP00000034588

UniGene: Mm.26743

Most popular with customers


Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2020 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1